Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2003
11/27/2003WO2003097591A1 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
11/27/2003WO2003097573A1 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
11/27/2003WO2003097163A2 Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
11/27/2003WO2003097110A1 Therapeutic target and uses thereof
11/27/2003WO2003097109A1 Improvements in delivery technology
11/27/2003WO2003097104A1 Treatment and prevention of tissue damage
11/27/2003WO2003097099A1 Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
11/27/2003WO2003097098A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003WO2003097071A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003WO2003097069A1 Trimegestone and estrogens for treating post menopausal disorders
11/27/2003WO2003097067A1 Combination of an ace inhibitor, a calcium channel blocker and a diuretic
11/27/2003WO2003097065A1 5-ht4 receptor antagonists for the treatment of heart failure
11/27/2003WO2003097063A1 Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators
11/27/2003WO2003097062A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
11/27/2003WO2003097056A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
11/27/2003WO2003097053A1 Compounds, compositions, and methods
11/27/2003WO2003097052A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
11/27/2003WO2003097047A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
11/27/2003WO2003097046A1 Method for treating obesity
11/27/2003WO2003097045A1 Combination of organic compounds
11/27/2003WO2003097042A1 Pgd2 receptor antagonist
11/27/2003WO2003097040A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003WO2003097033A2 Novel neutracetical and pharmaceutical compositions and their uses
11/27/2003WO2003097028A1 Use of edg receptor binding agents in cancer
11/27/2003WO2003097024A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003WO2003097019A1 Multilamellar system for the administration of active agents by means of ingestion
11/27/2003WO2003096808A1 Prevention or treatment of abnormal lipoprotein, cholestasis and atherosclerosis
11/27/2003WO2003084464A3 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
11/27/2003WO2003082189A3 Method for producing pseudo islets
11/27/2003WO2003078568A3 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
11/27/2003WO2003076469A3 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
11/27/2003WO2003074508B1 Compounds and methods of treating cell proliferative diseases
11/27/2003WO2003070765A3 Growth hormone fusion protein
11/27/2003WO2003069302A3 Alpha-substituted arylalkyl phosphonate derivatives
11/27/2003WO2003066594A3 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/27/2003WO2003065983A3 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/27/2003WO2003064622A3 Aggrecanase molecules
11/27/2003WO2003056899A3 Nitric oxide donors for treatment of disease and injury
11/27/2003WO2003055505A3 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders
11/27/2003WO2003053354A3 Fused cyclic modulators of nuclear hormone receptor function
11/27/2003WO2003053336A3 Methods for the treatment of peripheral neural and vascular ailments
11/27/2003WO2003051879A8 Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
11/27/2003WO2003040119A8 Angiogenesis inhibitors
11/27/2003WO2003039446A3 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
11/27/2003WO2003032965A3 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
11/27/2003WO2003032964A3 Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
11/27/2003WO2003028649A3 Novel composition of carvedilol
11/27/2003WO2003022852A3 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
11/27/2003WO2003020759A3 A caspase- 8 binding protein, its preparation and use
11/27/2003WO2003018038A3 Composition for the treatment of varicose veins
11/27/2003WO2003015717A3 Tyrosine kinase inhibitors
11/27/2003WO2003014064A8 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
11/27/2003WO2003013590A8 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
11/27/2003WO2003011207A3 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
11/27/2003WO2003008443A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/27/2003WO2003007888A3 Fat accumulation-modulating compounds
11/27/2003WO2003005971A3 Tetracycline compounds having target therapeutic activities
11/27/2003WO2002100813A3 Modulators of peroxisome proliferator activated receptors
11/27/2003WO2002092004A8 Use of hmg fragment as anti-inflammatory agents
11/27/2003WO2002086156A3 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
11/27/2003WO2002085940A3 New polynucleotides and polypeptides of the erythropoietin gene
11/27/2003WO2002074735A3 Biurethane derivatives
11/27/2003WO2002066617A8 Method for detecting a risk of hypertension and uses thereof
11/27/2003WO2002064791A3 Proteins and nucleic acids encoding same
11/27/2003WO2002061109A3 Yeast strains autonomously producing steroids
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003US20030221207 Cardiac-specific 11beta hydroxysteroid dehydrogenase type 2 transgenic mice
11/27/2003US20030221206 Using in vitro fertilization to produce gentically engineered animals for use as models for prevention and treatment of disease
11/27/2003US20030221199 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
11/27/2003US20030220494 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/27/2003US20030220489 29 human secreted proteins
11/27/2003US20030220480 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
11/27/2003US20030220478 Novel compounds
11/27/2003US20030220468 Modified forms of pharmacologically active agents and uses therefor
11/27/2003US20030220398 Administering rosmarinic acid, curcumin, phenethyl caffeate or 3-caffeoylquinic acid as hypotensive agents
11/27/2003US20030220393 Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them
11/27/2003US20030220385 Nitrogen compounds such as 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)-6-fluoroindazole, administered as phosphodiesterases inhibitors for prophylaxis of cardiovascular or sexual disorders, or as hypotensive agents
11/27/2003US20030220382 Amines such as 2-((2-N,N-di-n-pentylamino)-indan-5-yl)amino-5 -nitro-benzoic acid, administered for prophylaxis of Alzheimer's disease
11/27/2003US20030220381 Administering to a mammal 8-(5-Methyl-2-phenyl-oxazol-4-yl)-2-(1,2,3)triazoles, or 8-(5-methyl-2-phenyl-oxazol-4-yl)-2-pyrrol-1-yl- derivative for treating, obesity, hyperglycemia, diabetes etc
11/27/2003US20030220375 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
11/27/2003US20030220373 Therapeutic uses of PPAR mediators
11/27/2003US20030220372 Imidazole compounds as anti-inflammatory and analgesic agents
11/27/2003US20030220371 Administering to a mammal an aromatic or heteroaromatic ring substituted triazole derivative to treat the conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, and obesity
11/27/2003US20030220368 Superior Na+ channel inhibition activity; antiarrhythmic agents
11/27/2003US20030220367 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists
11/27/2003US20030220362 Novel inhibitors of formation of advanced glycation endproducts (AGEs)
11/27/2003US20030220359 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
11/27/2003US20030220358 A1 adenosine receptro antagonists
11/27/2003US20030220356 ABCA-1 elevating compounds
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220345 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones
11/27/2003US20030220344 Method of treating arrhythmias
11/27/2003US20030220341 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
11/27/2003US20030220339 Heterocyclic arylsulfonamidobenzylic compounds
11/27/2003US20030220332 Useful in the treatment of inter alia benign prostatic hyperplasia
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030220318 New phenylalanine derivatives
11/27/2003US20030220316 Such as N-(1-(1-methylethyl)piperidin-4-yl)-N-((4-methyl phenyl)methyl)-4-methoxyphenylacetamide for stimulation of serotonin receptors
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
1 ... 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 ... 1595